sponsored
PatientsVille.com Logo

PatientsVille

Fosrenol Medical Research Studies

Up-to-date List of Fosrenol Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Fosrenol Medical Research Studies

Rank Status Study
1 Recruiting Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan
Condition: Hyperphosphatemia
Intervention: Drug: Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet
Outcome Measures: Incidence of adverse drug reactions in subjects who received Fosrenol;   Incidence of serious adverse events in subjects who received Fosrenol;   Incidence of adverse drug reactions in subpopulation with baseline data [such as demographic data, concomitant disease, duration of treatment, maximum daily dose] and dose of Fosrenol;   Effectiveness evaluation assessment [achievement rate of a goal phosphate level; 3.5-6 mg/dL];   Effectiveness evaluation assessment [achievement rate of a goal calcium level; 8.4-10.0 mg/dL];   Clinical test value collections [calciotropic hormones, bone turnover markers]
2 Recruiting Fosrenol Post-marketing Surveillance for Hemodialysis in Japan
Condition: Hyperphosphatemia
Intervention: Drug: Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet
Outcome Measures: Incidence of adverse drug reactions in subjects who received Fosrenol;   Incidence of serious adverse events in subjects who received Fosrenol;   Incidence of adverse drug reactions in subpopulation with baseline data [such as demographic data, concomitant disease, duration of treatment, maximum daily dose] and dose of Fosrenol;   Effectiveness evaluation assessment [achievement rate of a goal phosphate level; 3.5-6 mg/dL];   Effectiveness evaluation assessment [achievement rate of a goal calcium level; 8.4-10.0 mg/dL];   Clinical test value collection: calciotropic hormones;   Clinical test value collection: bone turnover markers
3 Recruiting Fosrenol Post-marketing Surveillance in Japan
Conditions: Hyperphosphatemia;   Kidney Disease
Intervention: Drug: Fosrenol (Lanthanum Carbonate, BAY77-1931)
Outcome Measures: Incidence/number of episodes of adverse drug reactions and adverse events;   Serum P level for six months after start of treatment with the drug in comparison with baseline (at the time of start of treatment with Fosrenol);   Serum intact PTH level for six months after start of treatment with the drug in comparison with baseline;   Serum P level at 12 months after starting the treatment with Lanthanum carbonate in comparison with baseline (at the time of starting the treatment with Fosrenol).;   Serum P level at the conduction of dialysis from 13 months after starting the treatment with Lanthanum carbonate in comparison with baseline (at the time of starting the treatment with Fosrenol).;   Serum intact PTH level at 12 months after starting the treatment with Lanthanum carbonate in comparison with baseline (at the time of starting the treatment with Lanthanum carbonate).;   Serum intact PTH level at the conduction of dialysis from 13 months after starting the treatment with Lanthanum carbonate in comparison with baseline (at the time of starting the treatment with Lanthanum carbonate).;   Adverse drug event rate related to the digestive system;   Incidence/number of episodes of adverse events for 6, 12 months ,and from month 13 to the conduction of dialysis after starting the treatment with Lanthanum carbonate.;   Incidence/number of episodes of adverse drug reactions for 6, 12 months ,and from month 13 to the conduction of dialysis after starting the treatment with Lanthanum carbonate according to patient characteristics and treatment with Lanthanum carbonate.
4 Recruiting Fosrenol and Phosphorus Balance - Lanthanum Carbonate
Conditions: Chronic Kidney Failure;   End-stage Renal Disease;   Disorders Associated With Peritoneal Dialysis
Intervention: Drug: lanthanum carbonate
Outcome Measures: Fecal Phosphorus and Body Phosphorus Balance;   Fecal Calcium and Nitrogen and Body Calcium and Nitrogen Balance;   Protein-nitrogen balance;   Gastrointestinal symptoms
5 Recruiting A Comparison of Lanthanum Carbonate and Calcium Carbonate in Children
Condition: Hyperphosphataemia in Chronic Kidney Disease
Interventions: Drug: Lanthanum carbonate;   Drug: Calcium carbonate
Outcome Measures: Percentage of subjects achieving age-specific Kidney Disease Outcomes Quality Initiative (KDOQI) targets for serum phosphorus;   Change from baseline in serum phosphorus at up to 8 weeks;   Change from Baseline in Calcium Levels at up to 8 weeks;   Change from baseline in Calcium-Phosphorous Product at up to 8 Weeks;   Maximum Plasma Concentration (Cmax) of Lanthanum Carbonate;   Area Under the Plasma Concentration-Time Curve from time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Lanthanum Carbonate;   Change from baseline in serum phosphorus at up to 10 Months;   Change from Baseline in Calcium Levels at up to 10 Months;   Change from baseline in Calcium-Phosphorous Product at up to 10 Months;   Change from baseline in Bone Alkaline Phosphatase (ALP) at Up to 10 Months;   Change from Baseline in Tartrate-Resistant Acid Phosphatase (TRAP) at Up to 10 Months;   Change from Baseline Osteocalcin levels at Up to 10;   Change from Baseline in Fibroblast Growth factor 23 (FGF-23) Levels at Up to 10 Months;   Change from Baseline in Parathyroid Hormone (PTH) Levels at Up to 10 Months;   Change from Baseline in Sclerostin Levels at Up to 10 Months;   Change from Baseline in Fetuin-A Levels at Up to 10 Months;   Change from Baseline in Height at up to 10 Months;   Change from Baseline in Weight at Up to 10 Months
6 Recruiting The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23
Condition: Other Nonspecific Abnormal Serum Enzyme Levels
Interventions: Drug: Lanthanum carbonate;   Drug: Calcium Carbonate
Outcome Measure: serum level of fibroblast growth factor
7 Unknown  Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction
Condition: Chronic Kidney Disease
Interventions: Other: Diet counseling;   Drug: Phosphorus binder
Outcome Measures: Designated safety measure; serum calcium;   Designated safety measure: phosphorus;   Changes in flow;   Other Changes
8 Recruiting Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study
Conditions: Hemodialysis;   Hyperphosphatemia
Interventions: Drug: Lanthanum Carbonate;   Drug: Calcium Carbonate
Outcome Measures: Cardiovascular event free survival time.;   Overall survival;   Secondary hyperparathyroidism free survival;   Hip fracture free survival;   Quality of life questionnaire (KDQOL-SF, v1.3);   Bone mineral density (DEXA)

These studies may lead to new treatments and are adding insight into Fosrenol etiology and treatment.

A major focus of Fosrenol research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Fosrenol